FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283812829> ?p ?o ?g. }

• W4283812829 endingPage "100529" @default.
• W4283812829 startingPage "100529" @default.
• W4283812829 abstract "Pre-acute-on-chronic liver failure (ACLF) is a distinct intermediate stage between acute decompensation (AD) and ACLF. However, identifying patients with pre-ACLF and predicting progression from AD to ACLF is difficult. This study aimed to identify pre-ACLF within 28 days, and to develop and validate a prediction model for ACLF in patients with HBV-related decompensated cirrhosis.In total, 1,736 patients with HBV-related cirrhosis and AD were enrolled from 2 large-scale, multicenter, prospective cohorts. ACLF occurrence within 28 days, readmission, and 3-month and 1-year outcomes were collected.Among 970 patients with AD without ACLF in the derivation cohort, the 94 (9.6%) patients with pre-ACLF had the highest 3-month and 1-year LT-free mortality (61.6% and 70.9%, respectively), which was comparable to those with ACLF at enrollment (57.1% and 67.1%); the 251 (25.9%) patients with unstable decompensated cirrhosis had mortality rates of 22.4% and 32.1%, respectively; while the 507 (57.9%) patients with stable decompensated cirrhosis had the best outcomes (1-year mortality rate of 2.6%). Through Cox proportional hazard regression, specific precipitants, including hepatitis B flare with HBV reactivation, spontaneous hepatitis B flare with high viral load, superimposed infection on HBV, and bacterial infection, were identified to be significantly associated with ACLF occurrence in the derivation cohort. A model that incorporated precipitants, indicators of systemic inflammation and organ injuries reached a high C-index of 0.90 and 0.86 in derivation and validation cohorts, respectively. The optimal cut-off value (0.22) differentiated high-risk and low-risk patients, with a negative predictive value of 0.95.Three distinct clinical courses of patients with AD are validated in the HBV-etiology population. The precipitants significantly impact on AD-ACLF transition. A model developed by the precipitant-systemic inflammation-organ injury framework could be a useful tool for predicting ACLF occurrence.NCT02457637 and NCT03641872.It was previously shown that patients with decompensated cirrhosis could be stratified into 3 groups based on their short-term clinical prognoses. Herein, we showed that this stratification applies to patients who develop cirrhosis as a result of hepatitis B virus infection. We also developed a precipitant-based model (i.e. a model that incorporated information about the exact cause of decompensation) that could predict the likelihood of these patients developing a very severe liver disease called acute-on-chronic liver failure (or ACLF)." @default.
• W4283812829 created "2022-07-06" @default.
• W4283812829 creator A5001492855 @default.
• W4283812829 creator A5004325598 @default.
• W4283812829 creator A5004684051 @default.
• W4283812829 creator A5006101921 @default.
• W4283812829 creator A5010494834 @default.
• W4283812829 creator A5010806376 @default.
• W4283812829 creator A5011540364 @default.
• W4283812829 creator A5012441370 @default.
• W4283812829 creator A5012677271 @default.
• W4283812829 creator A5012712718 @default.
• W4283812829 creator A5021081788 @default.
• W4283812829 creator A5023238197 @default.
• W4283812829 creator A5025856206 @default.
• W4283812829 creator A5027337916 @default.
• W4283812829 creator A5028490219 @default.
• W4283812829 creator A5032235768 @default.
• W4283812829 creator A5032788646 @default.
• W4283812829 creator A5032883942 @default.
• W4283812829 creator A5033399666 @default.
• W4283812829 creator A5035282947 @default.
• W4283812829 creator A5054001746 @default.
• W4283812829 creator A5055278104 @default.
• W4283812829 creator A5055693377 @default.
• W4283812829 creator A5057590467 @default.
• W4283812829 creator A5059386453 @default.
• W4283812829 creator A5059639730 @default.
• W4283812829 creator A5059785863 @default.
• W4283812829 creator A5059919967 @default.
• W4283812829 creator A5060470951 @default.
• W4283812829 creator A5061043627 @default.
• W4283812829 creator A5069190300 @default.
• W4283812829 creator A5069706660 @default.
• W4283812829 creator A5070573479 @default.
• W4283812829 creator A5071140321 @default.
• W4283812829 creator A5071607713 @default.
• W4283812829 creator A5074160086 @default.
• W4283812829 creator A5081782546 @default.
• W4283812829 creator A5082022739 @default.
• W4283812829 creator A5082322894 @default.
• W4283812829 creator A5086326013 @default.
• W4283812829 creator A5086664284 @default.
• W4283812829 creator A5089259258 @default.
• W4283812829 creator A5091816996 @default.
• W4283812829 date "2022-10-01" @default.
• W4283812829 modified "2023-09-28" @default.
• W4283812829 title "Role of precipitants in transition of acute decompensation to acute-on-chronic liver failure in patients with HBV-related cirrhosis" @default.
• W4283812829 cites W1866275612 @default.
• W4283812829 cites W1993653707 @default.
• W4283812829 cites W2007670274 @default.
• W4283812829 cites W2116345964 @default.
• W4283812829 cites W2118765712 @default.
• W4283812829 cites W2120058397 @default.
• W4283812829 cites W2128385759 @default.
• W4283812829 cites W2411730197 @default.
• W4283812829 cites W2661272977 @default.
• W4283812829 cites W2749542756 @default.
• W4283812829 cites W2753521833 @default.
• W4283812829 cites W2755186880 @default.
• W4283812829 cites W2784039673 @default.
• W4283812829 cites W2791839818 @default.
• W4283812829 cites W2801431769 @default.
• W4283812829 cites W2802906787 @default.
• W4283812829 cites W2803208259 @default.
• W4283812829 cites W2893835498 @default.
• W4283812829 cites W2901302823 @default.
• W4283812829 cites W2943424730 @default.
• W4283812829 cites W2985510211 @default.
• W4283812829 cites W3002179283 @default.
• W4283812829 cites W3004440199 @default.
• W4283812829 cites W3007567227 @default.
• W4283812829 cites W3043538464 @default.
• W4283812829 cites W3048086500 @default.
• W4283812829 cites W3100863243 @default.
• W4283812829 cites W3120044720 @default.
• W4283812829 cites W3120669203 @default.
• W4283812829 cites W3165011897 @default.
• W4283812829 cites W3166743443 @default.
• W4283812829 cites W3212341555 @default.
• W4283812829 cites W4205196109 @default.
• W4283812829 cites W4210986718 @default.
• W4283812829 doi "https://doi.org/10.1016/j.jhepr.2022.100529" @default.
• W4283812829 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36052222" @default.
• W4283812829 hasPublicationYear "2022" @default.
• W4283812829 type Work @default.
• W4283812829 citedByCount "6" @default.
• W4283812829 countsByYear W42838128292022 @default.
• W4283812829 countsByYear W42838128292023 @default.
• W4283812829 crossrefType "journal-article" @default.
• W4283812829 hasAuthorship W4283812829A5001492855 @default.
• W4283812829 hasAuthorship W4283812829A5004325598 @default.
• W4283812829 hasAuthorship W4283812829A5004684051 @default.
• W4283812829 hasAuthorship W4283812829A5006101921 @default.
• W4283812829 hasAuthorship W4283812829A5010494834 @default.
• W4283812829 hasAuthorship W4283812829A5010806376 @default.
• W4283812829 hasAuthorship W4283812829A5011540364 @default.
• W4283812829 hasAuthorship W4283812829A5012441370 @default.

• next